Stoke Therapeutics (STOK) director receives grant of 17,786 stock options

Rhea-AI Filing Summary

Stoke Therapeutics director Arthur Tzianabos received a grant of options for 17,786 shares of common stock. The Director Stock Option has an exercise price of $29.46 per share and expires on June 2, 2036. It will vest in full on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, subject to his continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider TZIANABOS ARTHUR

Role null

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy)	17,786	$0.00	--

Holdings After Transaction: Director Stock Option (Right to Buy) — 17,786 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 17,786 options Exercise price: $29.46 per share Expiration date: June 2, 2036 +2 more

5 metrics

Option grant size 17,786 options Director Stock Option grant on June 3, 2026

Exercise price $29.46 per share Strike price for Director Stock Option

Expiration date June 2, 2036 Director Stock Option term end

Post-grant derivative holdings 17,786 options Total derivative securities following transaction

Vesting trigger date June 3, 2027 or next annual meeting Full vesting contingent on continued service

Key Terms

Director Stock Option, exercise price, expiration date, vesting

4 terms

Director Stock Option financial

"security_title: "Director Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "29.4600" per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-02T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"The option shall vest in full on the earlier of June 3, 2027 or the date of the issuer's next annual meeting"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TZIANABOS ARTHUR

(Last) (First) (Middle)

C/O STOKE THERAPEUTICS, INC.

45 WIGGINS AVENUE

(Street)

BEDFORD MASSACHUSETTS 01730

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Stoke Therapeutics, Inc. [ STOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$29.46	06/03/2026		A		17,786		(1)	06/02/2036	Common Stock	17,786	$0	17,786	D

Explanation of Responses:

1. The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.

	/s/ Jonathan Allan, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Stoke Therapeutics (STOK) report for Arthur Tzianabos?

Stoke Therapeutics reported that director Arthur Tzianabos received a grant of stock options covering 17,786 shares of common stock. These options are part of his director compensation and give him the right to buy shares at a fixed exercise price if they vest.

What is the exercise price of the new Arthur Tzianabos options at Stoke Therapeutics (STOK)?

The new director stock option granted to Arthur Tzianabos has an exercise price of $29.46 per share. This is the fixed price at which he can purchase common stock if he exercises the option after it vests and before expiration.

When do Arthur Tzianabos’s newly granted Stoke Therapeutics (STOK) options vest?

The options granted to Arthur Tzianabos vest in full on the earlier of June 3, 2027, or the date of Stoke Therapeutics’ next annual stockholder meeting. Vesting is conditioned on his continued service to the company through that vesting date.

What is the expiration date of Arthur Tzianabos’s new options at Stoke Therapeutics (STOK)?

Arthur Tzianabos’s director stock option expires on June 2, 2036. After this expiration date, he can no longer exercise the option to purchase shares, even if it has vested and was not previously exercised during its term.

How many options does Arthur Tzianabos hold in Stoke Therapeutics (STOK) after this grant?

Following this grant, Arthur Tzianabos holds 17,786 derivative securities in the form of director stock options. This total equals the number of options granted in the transaction, reflecting his full reported option position after the award.